Biotech

All Articles

AstraZeneca articles information on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early check out the performance of its own internal antibody...

iTeos- GSK's TIGIT celebrity presents relevant remodeling

.After declaring a period 3 launch based on positive midstage outcomes, iTeos and GSK are eventually...

More collective FDA may increase uncommon ailment R&ampD: document

.The FDA ought to be actually much more open and collective to discharge a rise in approvals of unco...

Zenas, MBX, Bicara scalp to Nasdaq in scorching time for biotech IPOs

.It's an unusually hectic Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bicara Therape...

Atea's COVID antiviral fails to halt hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has actually fallen short yet another COVID-19 trial, yet the biote...

Neurocrine's proposal to spare mental illness possibility falls short

.Neurocrine Biosciences' schizophrenia plan pivot has actually neglected. The biotech was incapable ...

Sanofi pays $110M upfront for late-stage radioligand treatment

.Sanofi has actually brought in a late access to the radioligand event, paying 100 thousand euros ($...

F 2G increases $100M for 2nd effort to get brand-new antifungal to market

.After F2G's initial try to acquire a new course of antifungal to market was actually hindered due t...

Moderna targets $1.1 B in R&ampD spending cuts, falls 5 systems among profitability stress

.Moderna has promised to cut R&ampD investing through $1.1 billion through 2027. The selection to re...

Sanofi's $80M bet on Fulcrum dystrophy medicine ends in stage 3 go under

.Only four months after Sanofi bet $80 thousand in upfront cash on Fulcrum Therapies' losmapimod, th...